2nd-gen stem cell-derived CAR gene therapy is more durable, effective against HIV
April 2, 2021 -- A novel second-generation chimeric antigen receptor (CAR)-based approach targeting HIV infection using the genetic modification of hematopoietic stem cells shows promise in preclinical models. The details of the study were published in PLOS Pathogens on April 1. Read More
Alloy raises $75M to advance biologics discovery platforms
April 2, 2021 -- Biotechnology ecosystem company Alloy Therapeutics announced it has closed $75 million in series C funding. Read More
New gene therapy could be effective in treating complex polygenic conditions
April 1, 2021 -- Scientists are applying gene therapy approaches in a new way by simultaneously administering a combination of cargos to treat complex polygenic neurodegenerative diseases with no single genetic cause. Details of the combination gene therapy in two animal models were detailed in a March 31 Science Advances article. Read More
Astellas establishes Astellas Gene Therapies to focus efforts
April 1, 2021 -- Astellas Pharma announced that it will integrate its wholly owned subsidiary, Audentes Therapeutics, and establish Astellas Gene Therapies within the organization. Genetic regulation will become one of the primary focuses of research and development strategy at Astellas. Read More
Scribe nabs $100M to advance CRISPR platform
April 1, 2021 -- Scribe Therapeutics has raised $100 million in financing, which will be used to further develop its suite of custom gene editing and delivery technologies, as well as advance a pipeline of therapeutics for neurodegeneration and other diseases with high unmet need. Read More
Gracell advances study, signs cell therapy deal
April 1, 2021 -- Gracell Biotechnologies has moved ahead with a cancer treatment research study and has signed a deal to manufacture its cell therapy products. Read More
Unchained Labs adds automated gene therapy, vaccine applications
April 1, 2021 -- Unchained Labs has rolled out new gene therapy and vaccine applications on its Big Tuna automated buffer exchange platform for biologics. The system can now buffer adeno-associated viruses and lipid nanoparticles. Read More
Charles River acquires Retrogenix for $48M
April 1, 2021 -- Charles River Laboratories has paid approximately $48 million U.S. to acquire the U.K.-based contract research organization Retrogenix. Read More
Prime editing creates desired gene mutations without collateral damage
March 30, 2021 -- A new gene editing tool called prime editing was demonstrated to efficiently create cell-specific knockout mice compared to traditional gene editing techniques. While both platforms successfully created mutations, prime editing did so without measurable on-target indels or off-targeting events, according to a study published in Genome Biology on March 16. Read More
Horizon Discovery offers new CRISPR reagents
March 30, 2021 -- Horizon Discovery, a PerkinElmer company, is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation reagents for CRISPR interference. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter